Better efficacy and significantly higher global success rate versus the gold standard fluconazole in the treatment of candidaemia*1
- Global success rate was significantly higher with anidulafungin versus fluconazole (75.6% vs 60.2%; p=0.02)*1
- Anidulafungin is more effective than fluconazole in severely ill patients2
- A secondary analysis showed that the global success rate with anidulafungin was also more effective than fluconazole in patients with critical illness† (70.8% vs 54.1%; p=0.03)2
Anidulafungin – effective in patients with deep-tissue candidiasis3
- In a pooled analysis of data from one randomised, double-blind, comparative study and four open-label, non-comparative studies:3
- The overall global success rate at EOIVT in patients with deep-tissue candidiasis was 79.1%
*Data at EOIVT for the MITT population, comprising 97% non-neutropenic and 3% neutropenic patients1.
†Critical illness was defined as an Acute Physiology and Chronic Health Evaluation (APACHE) II score ≥15, evidence of severe sepsis and/or patient was in intensive care.2
EOIVT, end of intravenous therapy; IV, intravenous; MITT, modified intention to treat.
- Reboli AC, et al. N Engl J Med 2007;356:2472-2482.
- Kett DH, et al. Critical Care 2011;15:R253.
- Aram J, et al. Abstract R691. Presented at the 24th ECCMID 2014.